Strategies for Success: Optimizing Antiretroviral Therapy in Heavily Treatment–Experienced Patients

Here’s my take on how to optimize the switching of antiretroviral therapy in patients with virologic suppression and a history of antiretroviral resistance.

Paul E. Sax, MD Released: October 17, 2022

Here’s why I think using newer novel agents earlier could affect virologic suppression and mortality for people with multidrug-resistant HIV.

Josep M. Llibre, MD, PhD Released: November 17, 2022

Lenacapavir is from a new drug class and may be a promising component of antiretroviral therapy if adherence can be ensured.

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Released: January 5, 2023

Here are my thoughts on the role of proviral DNA genotypic resistance testing for treatment-experienced people with HIV when switching ART in the setting of viral suppression, including when switching to long-acting ART.

José R. Arribas, MD Released: February 6, 2023